Approved by the FDA in 1991 with indications for acceleration of neutrophil recovery in several clinical settings, CSFs may prove clinically useful in ways beyond hemorestoration. Myeloprotection conferred by GM-CSF may enable higher doses of chemotherapy to be given with only short intervals between cycles. Priming may make resting AML blasts more chemosensitive. Mobilization of peripheral blood stem cells may facilitate and even improve autologous stem cell transplantation.
No takes yet. Share an insight, caveat, or question.
Hal E. Broxmeyer (1995) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: